26429-99-2

Basic information

• Product Name: Methyl (2E)-3-cyclohexylprop-2-enoate
• Synonyms: METHYL (2E)-3-CYCLOHEXYLPROP-2-ENOATE
• CAS NO: 26429-99-2
• Molecular Formula: C₁₀H₁₆O₂
• Molecular Weight: 168.23
• Mol File: 26429-99-2.mol
• Article Data: 33

Chemical Properties

• Boiling Point: 227.1 °C at 760 mmHg
• Flash Point: 103.2 °C
• Appearance: /
• Density: 1.036 g/cm³
• CAS DataBase Reference: Methyl (2E)-3-cyclohexylprop-2-enoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl (2E)-3-cyclohexylprop-2-enoate(26429-99-2)
• EPA Substance Registry System: Methyl (2E)-3-cyclohexylprop-2-enoate(26429-99-2)

Safety Data

• Hazardous Substances Data: 26429-99-2(Hazardous Substances Data)

Usage

General Description

Methyl (2E)-3-cyclohexylprop-2-enoate is a chemical compound with the molecular formula C11H18O2. It is classified as an ester, which is a type of organic compound formed by the reaction of an alcohol with an organic acid. This specific ester is derived from the combination of methanol and (2E)-3-cyclohexylprop-2-enoic acid. It is commonly used as a flavoring agent in the food industry, providing a fruity, pineapple-like aroma that is often used in the production of confectionery, beverages, and baked goods. Additionally, it is also used in the fragrance industry to impart a sweet and floral scent to perfumes and personal care products. Overall, methyl (2E)-3-cyclohexylprop-2-enoate is a versatile chemical with various applications in the food and fragrance industries.

Upstream product

• 15790-87-1 Methyl (E)-2-pentenoate 
• 110-82-7 cyclohexane 
• 88738-78-7 bis-(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate 
• 2043-61-0 cyclohexanecarbaldehyde 
• 319488-96-5 C₁₇H₁₈NO₄P 
• 701-98-4 β-cyclohexylidenepropionic acid 
• 77-78-1 dimethyl sulfate 
• 1529-78-8 [(methoxycarbonyl)methyl]triphenylarsonium bromide 
• 96-32-2 bromoacetic acid methyl ester 
• 67-56-1 methanol 
• 931-48-6 2-cyclohexylacetylene 
• 201230-82-2 carbon monoxide 
• 1067-74-9 Methyl diethylphosphonoacetate 
• 24371-94-6 cyclohexylmercury chloride 

Downstream Products

• 601560-12-7 3-cyclohexyl-2-hydroxy-3-oxo-propionic acid methyl ester 
• 72733-86-9 (R,S)-3-cyclohexyl-butyl-4-aminobutyric acid 

Relevant articles and documents

Ligand-controlled cobalt-catalyzed remote hydroboration and alkene isomerization of allylic siloxanes

The Co-catalyzed remote hydroboration and alkene isomerization of allylic siloxanes were realized by a ligand-controlled strategy. The remote hydroboration with dcype provided borylethers, while xantphos favored the formation of silyl enol ethers.

Copper-catalyzed vinylogous aerobic oxidation of unsaturated compounds with air

A mild and operationally simple copper-catalyzed vinylogous aerobic oxidation of β,γ- and α,β-unsaturated esters is described. This method features good yields, broad substrate scope, excellent chemo- and regioselectivity, and good functional group tolerance. This method is additionally capable of oxidizing β,γ- and α,β-unsaturated aldehydes, ketones, amides, nitriles, and sulfones. Furthermore, the present catalytic system is suitable for bisvinylogous and trisvinylogous oxidation. Tetramethylguanidine (TMG) was found to be crucial in its role as a base, but we also speculate that it serves as a ligand to copper(II) triflate to produce the active copper(II) catalyst. Mechanistic experiments conducted suggest a plausible reaction pathway via an allylcopper(II) species. Finally, the breadth of scope and power of this methodology are demonstrated through its application to complex natural product substrates.

1-PHENYLPYRROLIDIN-2-ONE DERIVATIVES AS PERK INHIBITORS

The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. The compounds of the invention are inhibitors of PERK and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases/injuries associated with activated unfolded protein response pathways, such as Alzheimer's disease, neuropathic pain, spinal cord injury, traumatic brain injury, ischemic stroke, stroke, Parkinson's disease, diabetes, metabolic syndrome, metabolic disorders, Huntington's disease, Creutzfeldt- Jakob Disease, fatal familial insomnia, Gerstmann-Str?ussler-Scheinker syndrome, and related prion diseases, amyotrophic lateral sclerosis, progressive supranuclear palsy, myocardial infarction, cardiovascular disease, inflammation, organ fibrosis, chronic and acute diseases of the liver, fatty liver disease, liver steatosis, liver fibrosis, chronic and acute diseases of the lung, lung fibrosis, chronic and acute diseases of the kidney, kidney fibrosis, chronic traumatic encephalopathy (CTE), neurodegeneration, dementias, frontotemporal dementias, tauopathies, Pick's disease, Neimann-Pick's disease, amyloidosis, cognitive impairment, atherosclerosis, ocular diseases, arrhythmias, in organ transplantation and in the transportation of organs for transplantation. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PERK activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.